Characterization of a novel extended-spectrum β-lactamase phenotype from OXA-1 expression in Salmonella Typhimurium strains from Africa and Ireland

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 4, 2011, Pages 549-553

  Boyle, Fiona ^a   Healy, Gerard ^a   Hale, James ^b   Kariuki, Samuel ^c   Cormican, Martin ^a,d   Morris, Dearbháile ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Africa; ESBL; Ireland; Salmonella enterica

Indexed keywords

AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; EXTENDED SPECTRUM BETA LACTAMASE OXA 1; GENTAMICIN; GUANINE; KANAMYCIN; MINOCYCLINE; NALIDIXIC ACID; RIFAMPICIN; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SUBSTRATE; ENZYME SYNTHESIS; GENE ACTIVATION; GENE INSERTION; HUMAN; INTEGRON; IRELAND; KENYA; MALAWI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; DNA, BACTERIAL; HUMANS; IRELAND; KENYA; MALAWI; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, INSERTIONAL; PROMOTER REGIONS, GENETIC; SALMONELLA TYPHIMURIUM;

EID: 79960366569     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.04.007     Document Type: Article

References (22)

1. Boyle F., Morris D., O'Connor J., DeLappe N., Ward J., Cormican M. First report of extended-spectrum-{beta}-lactamase-producing Salmonella enterica serovar Kentucky isolated from poultry in Ireland. Antimicrob. Agents Chemother. 2010, 54:551-553.
2. British Society for Antimirobial Chemotherapy (BSAC) Methods for Antimicrobial Susceptibility Testing. Version 71, February 2008.
3. Carattoli A., Bertini A., Villa L., Falbo V., Hopkins K.L., Threlfall E.J. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods 2005, 63:219-228.
4. Carmichael G. ESBLs: the next challenge in infection control. Lancet Infect. Dis. 2004, 4:480.
5. Clinical Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement. M100-S17 2007, CLSI, Wayne, PA.
6. Clinical Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Seventh Edition 2007, CLSI, Wayne, PA.
7. Clinical Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. M100-S20 2010, CLSI, Wayne, PA.
8. Coudron P.E., Moland E.S., Sanders C.C. Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J. Clin. Microbiol. 1997, 35:2593-2597.
9. Dubois V., Arpin C., Quentin C. Decreased susceptibility to cefepime in a clinical strain of Escherichia coli related to plasmid- and integron-encoded oxa-30 β-lactamase. Antimicrob. Agents Chemother. 2003, 47:2380-2381.
10. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 1.0. December 2009 2009, http://www.eucast.org/clinical_breakpoints/.
11. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3. January 2011 2011, http://www.eucast.org/clinical_breakpoints/.
12. HPA (2006) Detection and reporting of bacteria with extended spectrum ß-lactamases, National Standard Method QSOP 51.
13. Jove T., Da Re S., Denis F., Mazel D., Ploy M.C. Inverse correlation between promoter strength and excision activity in class 1 integrons. PLoS Genet. 2010, 6:e1000793.
14. Kariuki S., Revathi G., Kariuki N., Muyodi J., Mwituria J., Munyalo A., Kagendo D., Murungi L., Anthony Hart C. Increasing prevalence of multidrug-resistant non-typhoidal salmonellae, Kenya, 1994-2003. Int. J. Antimicrob. Agents 2005, 25:38-43.
15. Kidgell C., Reichard U., Wain J., Linz B., Torpdahl M., Dougan G., Achtman M. Salmonella typhi, the causative agent of typhoid fever, is approximately 50,000 years old. Infect. Genet. Evol. 2002, 2:39-45.
16. Kingsley R., Msefula C., Thomson N., Kariuki S., Holt K., Gordon M., Harris D., Clarke L., Whitehead S., Sangal V., Marsh K., Achtman M., Molyneux M., Cormican M., Parkhill J., MacLennan C., Heyderman R., Dougan G. Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res. 2009, 19:2279-2287.
17. Matthew M., Harrisa M., Marshall M.J., Ross G.W. The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J. Gen. Microbiol. 1975, 169-178.
18. Miro E., Navarro F., Mirelis B., Sabate M., Rivera A., Coll P., Prats G. Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period. Antimicrob. Agents Chemother. 2002, 46:3991-3994.
19. Morris D., O'Hare C., Glennon M., Maher M., Corbett-Feeney G., Cormican M. Extended-spectrum {beta}-lactamases in Ireland, including a novel enzyme, TEM-102. Antimicrob. Agents Chemother. 2003, 47:2572-2578.
20. Morris D., Whelan M., Corbett-Feeney G., Cormican M., Hawkey P., Li X., Doran G. First report of extended-spectrum-beta-lactamase-producing Salmonella enterica isolates in Ireland. Antimicrob. Agents Chemother. 2006, 50:1608-1609.
21. Oliver A., Weigel L., Rasheed J., McGowan J., Raney P., Tenover F. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob. Agents Chemother. 2002, 46:3829-3836.
22. Swaminathan B., Barrett T.J., Hunter S.B., Tauxe R.V. PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg. Infect. Dis. 2001, 7:382-389.